GlassScriptPhysician profile
Joshua Michael Bauml
NPI 1740449487
$144,221.49
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $56K · 2020: $47K · 2021: $35K · 2022: $6,690.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $33,604.86 | 2019-2021 | |
| Genentech USA, INC. | $15,322.91 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12,312.75 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $11,435.65 | 2019-2022 | |
| Amgen INC. | $11,057.99 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $10,937.50 | 2019-2020 | |
| Astrazeneca Uk Limited | $9,104.80 | 2019 | |
| Daiichi Sankyo INC. | $8,502.50 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $5,554.92 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $4,040.00 | 2021 | |
| Agilent Technologies, INC. | $3,866.00 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $3,150.00 | 2020-2021 | |
| Janssen Biotech, INC. | $3,090.00 | 2021 | |
| Regeneron Pharmaceuticals, INC. | $2,360.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $2,280.00 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Foundation Medicine, INC. | $1,750.00 | 2020 | |
| Janssen Global Services, LLC | $1,550.00 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $1,500.00 | 2021 | |
| Eli Lilly and Company | $1,400.00 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,300.00 | 2020-2021 | |
| Genentech, INC. | $78.66 | 2019 | |
| Incyte Corporation | $22.95 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Research and ownership
$3,107.74 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Bauml listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.